798 related articles for article (PubMed ID: 29947083)
1. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
2. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
[TBL] [Abstract][Full Text] [Related]
3. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
[TBL] [Abstract][Full Text] [Related]
4. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review.
Lafage-Proust MH
Ther Adv Rare Dis; 2022; 3():26330040221074702. PubMed ID: 37180412
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Brandi ML; Jan de Beur S; Briot K; Carpenter T; Cheong HI; Cohen-Solal M; Crowley RK; Eastell R; Imanishi Y; Imel EA; Ing SW; Insogna K; Ito N; Javaid K; Kamenicky P; Keen R; Kubota T; Lachmann RH; Perwad F; Pitukcheewanont P; Portale A; Ralston SH; Tanaka H; Weber TJ; Yoo HW; Sun W; Williams A; Nixon A; Takeuchi Y
Calcif Tissue Int; 2022 Oct; 111(4):409-418. PubMed ID: 35927518
[TBL] [Abstract][Full Text] [Related]
6. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
8. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
9. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
[TBL] [Abstract][Full Text] [Related]
10. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
11. Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review.
Jurca CM; Iuhas O; Kozma K; Petchesi CD; Zaha DC; Bembea M; Jurca S; Paul C; Jurca AD
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011303
[TBL] [Abstract][Full Text] [Related]
12. Burosumab: First Global Approval.
Lamb YN
Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
[TBL] [Abstract][Full Text] [Related]
13. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Balani S; Perwad F
Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
[TBL] [Abstract][Full Text] [Related]
14. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
15. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
[TBL] [Abstract][Full Text] [Related]
17. Real-world data of Brazilian adults with X-linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts.
Vaisbich MH; de Cillo ACP; Silva BCC; DÁlva CB; de Carvalho ÉH; de Almeida JMCM; Marques LLM; Ribeiro M; da Silva MBM; de Medeiros PFV; Mendes PH
Mol Genet Genomic Med; 2024 Feb; 12(2):e2387. PubMed ID: 38337160
[TBL] [Abstract][Full Text] [Related]
18. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial.
Fratzl-Zelman N; Hartmann MA; Gamsjaeger S; Rokidi S; Paschalis EP; Blouin S; Zwerina J
J Bone Miner Res; 2022 Sep; 37(9):1665-1678. PubMed ID: 35775373
[TBL] [Abstract][Full Text] [Related]
19. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
